{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:23:27Z","timestamp":1783596207864,"version":"3.55.0"},"reference-count":28,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>This case highlights the use of intravenous immunoglobulin (IVIG) in a patient with refractory pure class V lupus nephritis (LN), a challenging subtype of LN. A woman in her 30s with systemic lupus erythematosus developed severe proteinuria and could not tolerate standard immunosuppressants due to life-threatening infections. IVIG, though not a guideline-recommended therapy for class V LN, was initiated as an alternative. Over a 6-month period, the urinary protein-to-creatinine ratio decreased significantly, resulting in sustained renal remission. IVIG\u2019s mechanism involves modulating immunity, neutralising autoantibodies and reducing inflammation with a favourable safety profile compared with glucocorticoids and mycophenolate. While the current literature lacks robust trials, case reports and limited studies suggest that IVIG has the potential to treat difficult-to-treat LN. This case highlights the potential role of IVIG in LN and advocates for further research to establish its efficacy in managing class V LN, particularly in patients unable to tolerate conventional therapies.<\/jats:p>","DOI":"10.1136\/bcr-2026-272497","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:35:22Z","timestamp":1783593322000},"page":"e272497","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Patient with class\u202fV lupus nephritis (LN) treated with intravenous immunoglobulin (IVIG) achieving a favourable outcome"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-6741","authenticated-orcid":false,"given":"Chen","family":"Chao","sequence":"first","affiliation":[{"name":"Rheumatology, Montefiore Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Pullman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montefiore Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement E","family":"Tagoe","sequence":"additional","affiliation":[{"name":"Rheumatology, Montefiore Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026070903351518000_19.7.e272497.1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/art.42375","article-title":"Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population\u2010Based Study Over Four Decades Using the Lupus Midwest Network","volume":"75","author":"Hocao\u01e7lu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026070903351518000_19.7.e272497.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24538"},{"key":"2026070903351518000_19.7.e272497.3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.31.020180.002335"},{"key":"2026070903351518000_19.7.e272497.4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040415"},{"key":"2026070903351518000_19.7.e272497.5","first-page":"297","article-title":"Mycophenolate mofetil in the treatment of lupus nephritis","volume":"2","author":"Yong","year":"2008","journal-title":"Biologics"},{"key":"2026070903351518000_19.7.e272497.6","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026070903351518000_19.7.e272497.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00443.x"},{"key":"2026070903351518000_19.7.e272497.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"2026070903351518000_19.7.e272497.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017"},{"key":"2026070903351518000_19.7.e272497.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"2026070903351518000_19.7.e272497.11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/M23-3236","article-title":"Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease\u202f: A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials","volume":"177","author":"Ku","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026070903351518000_19.7.e272497.12","article-title":"Intravenous immunoglobulin in the management of lupus nephritis","volume":"2012","author":"Wenderfer","year":"2012","journal-title":"Autoimmune Dis"},{"key":"2026070903351518000_19.7.e272497.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03955.x","article-title":"Mechanisms of action of immune globulin","volume":"157 Suppl 1","author":"Fern\u00e1ndez-Cruz","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2026070903351518000_19.7.e272497.14","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1423.044"},{"key":"2026070903351518000_19.7.e272497.15","doi-asserted-by":"crossref","first-page":"103182","DOI":"10.1016\/j.autrev.2022.103182","article-title":"Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature","volume":"21","author":"Cajamarca-Bar\u00f3n","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2026070903351518000_19.7.e272497.16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.1.332"},{"key":"2026070903351518000_19.7.e272497.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5503.484"},{"key":"2026070903351518000_19.7.e272497.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse Effects of Immunoglobulin Therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"2026070903351518000_19.7.e272497.19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials","volume":"76","author":"Figueroa-Parra","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026070903351518000_19.7.e272497.20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/art.39849","article-title":"Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications","volume":"69","author":"Feldman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026070903351518000_19.7.e272497.21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173893","article-title":"The Role of Intravenous Immunoglobulin (IVIG) in Reducing Infection Risk in Multiple Myeloma (MM) Patients Receiving Immune-Based Therapies: A Single Center Experience","volume":"142","author":"Lim","year":"2023","journal-title":"Blood"},{"key":"2026070903351518000_19.7.e272497.22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s12026-018-9047-y","article-title":"Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature","volume":"66","author":"Lidar","year":"2018","journal-title":"Immunol Res"},{"key":"2026070903351518000_19.7.e272497.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01575-5"},{"key":"2026070903351518000_19.7.e272497.24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000086","article-title":"Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis","volume":"93","author":"Sakthiswary","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2026070903351518000_19.7.e272497.25","unstructured":"Monova D , Monov S . Treatment of Active Lupus Nephritis:Intravenous Immunoglobulin G versus Cyclophosphamide or Azathioprine. BANTAO J 2006;4."},{"key":"2026070903351518000_19.7.e272497.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(00)80018-9"},{"key":"2026070903351518000_19.7.e272497.27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026070903351518000_19.7.e272497.28","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.76"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-272497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:35:24Z","timestamp":1783593324000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-272497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bcr-2026-272497"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-272497","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}